Neurodegenerative Disease Market Size, Share, and Outlook, H2-2025 Report- By Indication (Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Huntington Disease, Others), By Drug (N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibit
Description
Neurodegenerative Disease Market Outlook
The global Neurodegenerative Disease Market Size is valued at $62.8 Billion in 2025 and is forecast to reach $104.2 Billion in 2032 at a CAGR of 7.5%.
The Neurodegenerative Disease Market continue to remain a steadily growing market and offers lucrative growth opportunities across the industry stakeholders from suppliers to distributors and end-use industries. This comprehensive market research report provides 12-year historic and forecast data on Neurodegenerative Disease Market segments across 22 countries from 2021 to 2032. Key segments covered include By Indication (Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Huntington Disease, Others), By Drug (N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs, Others), offering granular insights into performance drivers and emerging patterns. With over 70 tables and charts, the report provides actionable findings based on extensive data modeling and industry surveys.
Neurodegenerative Disease Market Insights, 2025
In 2025, the neurodegenerative disease market is advancing with therapies targeting molecular mechanisms underlying Alzheimer’s, Parkinson’s, and ALS. Disease-modifying agents, monoclonal antibodies, and gene therapies are emerging alongside symptomatic treatments to improve quality of life. Early detection using biomarkers, imaging, and digital cognitive assessments is becoming increasingly important for therapy initiation. Personalized treatment strategies based on genetic profiling and disease progression are gaining traction. Digital therapeutics, wearable monitoring, and telehealth platforms are being integrated for remote disease management. Regulatory agencies are emphasizing safety, efficacy, and post-marketing surveillance due to complex disease biology. Research into combination therapies and neuroprotective agents is expanding. Overall, the market reflects innovation, early intervention, and patient-centered management of progressive neurological disorders.
Five Trends Shaping the Global Neurodegenerative Disease Market in 2025 and Beyond
The global Neurodegenerative Disease Industry is undergoing a paradigm shift driven by regulatory changes, technological innovation, and sustainability imperatives. Amidst intense demand growth from diverse end-users, companies are focusing on new product launches to cater to individual applications. Companies are also emphasizing operational resilience and circular economy principles and are aligning strategies to secure long-term growth. The report identifies key structural changes, disruptive technologies, and evolving trade flows influencing competitiveness, helping stakeholders strengthen decision-making for both the short and long term.
What are the Biggest Opportunities for Growth in the Neurodegenerative Disease Industry?
The Neurodegenerative Disease Market sector has shown strong adaptability amid volatility in prices, supply chain disruptions, and geopolitical tensions. Moving forward, potential opportunities lie in niche products, aggressive distribution activities, and digital process optimization. With increasing demand from emerging markets, Neurodegenerative Disease Market is positioned for growth through 2030 and beyond. This chapter provides a strategic perspective for businesses to identify revenue-generating avenues, mitigate risks, and adopt innovative pathways for expansion.
Neurodegenerative Disease Market Segment Insights
The Neurodegenerative Disease Industry offers diverse opportunities across product types, applications, and distribution channels. The analytical report provides detailed forecasts across diverse segments including By Indication (Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Huntington Disease, Others), By Drug (N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs, Others). Insights cover the largest and fastest-growing product types, applications, and regions, highlighting drivers behind each segment. Market outlooks are provided for five regions—Asia Pacific, North America, Europe, South America, and Middle East & Africa—with country-level forecasts for 22 markets through 2032.
Neurodegenerative Disease Industry Value Chain
The chapter identifies potential companies and their operations across the global Neurodegenerative Disease Industry ecosystem. It assists decision-makers in evaluating global Neurodegenerative Disease Market fundamentals, market dynamics, and disruptive trends across the value chain segments. According to the International Council of Chemical Associations (ICCA), chemicals underpin over 95% of manufactured products worldwide.
Scenario Analysis and Forecasts
Strategic planning in the Neurodegenerative Disease Industry requires resilience to uncertain macroeconomic and regulatory conditions. To guide stakeholders, the report offers three scenario forecasts—low growth, reference case, and high growth—enabling companies to align strategies under different market conditions.
Asia Pacific Neurodegenerative Disease Market Analysis – Hub of Industrial Transformation
Asia Pacific continues to be the largest and fastest-growing region for Neurodegenerative Disease Market, underpinned by rapid industrialization, large-scale infrastructure development, and rising consumption across emerging economies. China, India, and Southeast Asia lead the demand surge, supported by investments in chemical parks, free trade agreements, and rising domestic manufacturing capacity. China remains the single largest producer and consumer of chemicals, accounting for over $1.5 trillion in chemical sales, followed by India, which is projected by the India Brand Equity Foundation (IBEF) to become a $300 billion chemicals market by 2025. Further, Japanese and South Korean markets remain stable with most companies focusing on new product launches and diversification of sales channels.
United States Neurodegenerative Disease Market Insights – Innovation and Specialty Leadership
The American Chemistry Council (ACC) projects steady annual demand growth for specialty and performance chemicals, particularly in automotive, electronics, agriculture, and construction applications. The US continues to lead in specialty and high-value-added chemicals, with investments focused on R&D, advanced process technologies, and digital manufacturing. In addition, the Canadian and Mexican markets offer lucrative growth pockets for manufacturers and vendors. Focus on private-brand offerings and promotions, diversified sales channels, expansion into niche segments, adoption of advanced technologies, and sustainability are widely observed across the North American Neurodegenerative Disease Market.
Europe Neurodegenerative Disease Market Outlook 2025 – Regulatory and Innovation-Driven Growth
Europe is one of the largest markets for Neurodegenerative Disease Market with demand from both Western Europe and Eastern European regions increasing over the medium to long-term future. The European chemical sector employs more than 1.2 million people directly and is highly influenced by the EU Green Deal, which aims for climate neutrality by 2050. With increasing adoption of advanced technologies, raw materials, and digital transformation, Europe remains a strategic hub for Neurodegenerative Disease Industry competitiveness. The report analyses the key Neurodegenerative Disease Market drivers and opportunities across Germany, France, the United Kingdom, Spain, Italy, Russia, and other Europe.
Latin American Neurodegenerative Disease Market outlook rebounds in line with economic growth
Optimistic economic outlook across Brazil, Argentina, Chile, and other South and Central American countries presents strong opportunities for domestic and international Neurodegenerative Disease Market companies. Increased consumer spending is estimated across markets over the next few quarters through 2026. Expanding trade partnerships, urbanization, and growing demand for specialty products underpin market prospects.
Middle East and Africa Neurodegenerative Disease Markets- New Opportunities for Companies Harnessing Diversity
The Middle East remains a key hub for Neurodegenerative Disease Market companies, with Saudi Arabia, UAE, and Qatar investing heavily in distribution networks. In addition, Africa presents strong growth potential in Nigeria, South Africa, and other emerging economies, with increasing demand for cost effective and accessible products. Investment strategies tailored to localized needs and sustainable growth will be crucial for success. In addition to Nigeria, Algeria, South Africa, and other markets, steady growth markets in Ethiopia, Rwanda, Ghana, Tanzania, the Democratic Republic of Congo, and others present significant prospects for companies.
Competitive Landscape – How Neurodegenerative Disease Market Companies Outcompete in 2025
The ability to adapt to changing regulations, sustainability imperatives, and customer-specific innovations defines leadership in the Neurodegenerative Disease Market. Companies are leveraging M&A activities, strategic joint ventures, and vertical integration to secure raw material access and strengthen downstream presence. The report profiles leading players, analyzing their 2024 revenues, market shares, R&D expenditures, and strategic directions. The report analyzes AbbVie Inc, Amneal Pharmaceuticals Inc, Biogen Inc, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd, Johnson & Johnson, Merck & Co. Inc, Novartis AG, Pfizer Inc, Sanofi SA, Teva Pharmaceutical Industries Ltd, UCB S.A.. Each company is benchmarked through a detailed SWOT and financial analysis, providing clients with insights into competitive positioning and innovation leadership.
Neurodegenerative Disease Market Scope
Leading Segments
By Indication
Parkinson's Disease
Alzheimer's Disease
Multiple Sclerosis
Huntington Disease
Others
By Drug
N-methyl-D-aspartate Receptor Antagonists
Cholinesterase Inhibitors
Dopamine Agonists
Immunomodulatory Drugs
Others
Leading Companies
AbbVie Inc
Amneal Pharmaceuticals Inc
Biogen Inc
Boehringer Ingelheim International GmbH
F. Hoffmann-La Roche Ltd
Johnson & Johnson
Merck & Co. Inc
Novartis AG
Pfizer Inc
Sanofi SA
Teva Pharmaceutical Industries Ltd
UCB S.A.
Geographies
North America- US, Canada, Mexico
Europe- Germany, France, UK, Spain, Italy, Nordics, BeNeLux, Others
Asia Pacific- China, India, Japan, South Korea, Australia, South East Asia, Others
Latin America- Brazil, Argentina, Others
Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
Reasons to Buy the Report Make informed decisions with 12-year forecasts across 22 countries and multiple market segments. Evaluate regulatory impacts, sustainability trends, and disruptive technologies shaping the chemicals industry. Gain insights into the competitive landscape, including company profiles, financials, and strategic moves. Build an integrated understanding of the chemicals ecosystem across upstream, midstream, and downstream operations. Leverage insights on circular economy initiatives, digitalization, and carbon-neutral strategies driving the next decade. Assess risks and opportunities with scenario-based forecasts tailored to different growth conditions. Access the report in multiple formats (PDF, Excel, PPT) for easier integration into strategic planning.
The global Neurodegenerative Disease Market Size is valued at $62.8 Billion in 2025 and is forecast to reach $104.2 Billion in 2032 at a CAGR of 7.5%.
The Neurodegenerative Disease Market continue to remain a steadily growing market and offers lucrative growth opportunities across the industry stakeholders from suppliers to distributors and end-use industries. This comprehensive market research report provides 12-year historic and forecast data on Neurodegenerative Disease Market segments across 22 countries from 2021 to 2032. Key segments covered include By Indication (Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Huntington Disease, Others), By Drug (N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs, Others), offering granular insights into performance drivers and emerging patterns. With over 70 tables and charts, the report provides actionable findings based on extensive data modeling and industry surveys.
Neurodegenerative Disease Market Insights, 2025
In 2025, the neurodegenerative disease market is advancing with therapies targeting molecular mechanisms underlying Alzheimer’s, Parkinson’s, and ALS. Disease-modifying agents, monoclonal antibodies, and gene therapies are emerging alongside symptomatic treatments to improve quality of life. Early detection using biomarkers, imaging, and digital cognitive assessments is becoming increasingly important for therapy initiation. Personalized treatment strategies based on genetic profiling and disease progression are gaining traction. Digital therapeutics, wearable monitoring, and telehealth platforms are being integrated for remote disease management. Regulatory agencies are emphasizing safety, efficacy, and post-marketing surveillance due to complex disease biology. Research into combination therapies and neuroprotective agents is expanding. Overall, the market reflects innovation, early intervention, and patient-centered management of progressive neurological disorders.
Five Trends Shaping the Global Neurodegenerative Disease Market in 2025 and Beyond
The global Neurodegenerative Disease Industry is undergoing a paradigm shift driven by regulatory changes, technological innovation, and sustainability imperatives. Amidst intense demand growth from diverse end-users, companies are focusing on new product launches to cater to individual applications. Companies are also emphasizing operational resilience and circular economy principles and are aligning strategies to secure long-term growth. The report identifies key structural changes, disruptive technologies, and evolving trade flows influencing competitiveness, helping stakeholders strengthen decision-making for both the short and long term.
What are the Biggest Opportunities for Growth in the Neurodegenerative Disease Industry?
The Neurodegenerative Disease Market sector has shown strong adaptability amid volatility in prices, supply chain disruptions, and geopolitical tensions. Moving forward, potential opportunities lie in niche products, aggressive distribution activities, and digital process optimization. With increasing demand from emerging markets, Neurodegenerative Disease Market is positioned for growth through 2030 and beyond. This chapter provides a strategic perspective for businesses to identify revenue-generating avenues, mitigate risks, and adopt innovative pathways for expansion.
Neurodegenerative Disease Market Segment Insights
The Neurodegenerative Disease Industry offers diverse opportunities across product types, applications, and distribution channels. The analytical report provides detailed forecasts across diverse segments including By Indication (Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Huntington Disease, Others), By Drug (N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs, Others). Insights cover the largest and fastest-growing product types, applications, and regions, highlighting drivers behind each segment. Market outlooks are provided for five regions—Asia Pacific, North America, Europe, South America, and Middle East & Africa—with country-level forecasts for 22 markets through 2032.
Neurodegenerative Disease Industry Value Chain
The chapter identifies potential companies and their operations across the global Neurodegenerative Disease Industry ecosystem. It assists decision-makers in evaluating global Neurodegenerative Disease Market fundamentals, market dynamics, and disruptive trends across the value chain segments. According to the International Council of Chemical Associations (ICCA), chemicals underpin over 95% of manufactured products worldwide.
Scenario Analysis and Forecasts
Strategic planning in the Neurodegenerative Disease Industry requires resilience to uncertain macroeconomic and regulatory conditions. To guide stakeholders, the report offers three scenario forecasts—low growth, reference case, and high growth—enabling companies to align strategies under different market conditions.
Asia Pacific Neurodegenerative Disease Market Analysis – Hub of Industrial Transformation
Asia Pacific continues to be the largest and fastest-growing region for Neurodegenerative Disease Market, underpinned by rapid industrialization, large-scale infrastructure development, and rising consumption across emerging economies. China, India, and Southeast Asia lead the demand surge, supported by investments in chemical parks, free trade agreements, and rising domestic manufacturing capacity. China remains the single largest producer and consumer of chemicals, accounting for over $1.5 trillion in chemical sales, followed by India, which is projected by the India Brand Equity Foundation (IBEF) to become a $300 billion chemicals market by 2025. Further, Japanese and South Korean markets remain stable with most companies focusing on new product launches and diversification of sales channels.
United States Neurodegenerative Disease Market Insights – Innovation and Specialty Leadership
The American Chemistry Council (ACC) projects steady annual demand growth for specialty and performance chemicals, particularly in automotive, electronics, agriculture, and construction applications. The US continues to lead in specialty and high-value-added chemicals, with investments focused on R&D, advanced process technologies, and digital manufacturing. In addition, the Canadian and Mexican markets offer lucrative growth pockets for manufacturers and vendors. Focus on private-brand offerings and promotions, diversified sales channels, expansion into niche segments, adoption of advanced technologies, and sustainability are widely observed across the North American Neurodegenerative Disease Market.
Europe Neurodegenerative Disease Market Outlook 2025 – Regulatory and Innovation-Driven Growth
Europe is one of the largest markets for Neurodegenerative Disease Market with demand from both Western Europe and Eastern European regions increasing over the medium to long-term future. The European chemical sector employs more than 1.2 million people directly and is highly influenced by the EU Green Deal, which aims for climate neutrality by 2050. With increasing adoption of advanced technologies, raw materials, and digital transformation, Europe remains a strategic hub for Neurodegenerative Disease Industry competitiveness. The report analyses the key Neurodegenerative Disease Market drivers and opportunities across Germany, France, the United Kingdom, Spain, Italy, Russia, and other Europe.
Latin American Neurodegenerative Disease Market outlook rebounds in line with economic growth
Optimistic economic outlook across Brazil, Argentina, Chile, and other South and Central American countries presents strong opportunities for domestic and international Neurodegenerative Disease Market companies. Increased consumer spending is estimated across markets over the next few quarters through 2026. Expanding trade partnerships, urbanization, and growing demand for specialty products underpin market prospects.
Middle East and Africa Neurodegenerative Disease Markets- New Opportunities for Companies Harnessing Diversity
The Middle East remains a key hub for Neurodegenerative Disease Market companies, with Saudi Arabia, UAE, and Qatar investing heavily in distribution networks. In addition, Africa presents strong growth potential in Nigeria, South Africa, and other emerging economies, with increasing demand for cost effective and accessible products. Investment strategies tailored to localized needs and sustainable growth will be crucial for success. In addition to Nigeria, Algeria, South Africa, and other markets, steady growth markets in Ethiopia, Rwanda, Ghana, Tanzania, the Democratic Republic of Congo, and others present significant prospects for companies.
Competitive Landscape – How Neurodegenerative Disease Market Companies Outcompete in 2025
The ability to adapt to changing regulations, sustainability imperatives, and customer-specific innovations defines leadership in the Neurodegenerative Disease Market. Companies are leveraging M&A activities, strategic joint ventures, and vertical integration to secure raw material access and strengthen downstream presence. The report profiles leading players, analyzing their 2024 revenues, market shares, R&D expenditures, and strategic directions. The report analyzes AbbVie Inc, Amneal Pharmaceuticals Inc, Biogen Inc, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd, Johnson & Johnson, Merck & Co. Inc, Novartis AG, Pfizer Inc, Sanofi SA, Teva Pharmaceutical Industries Ltd, UCB S.A.. Each company is benchmarked through a detailed SWOT and financial analysis, providing clients with insights into competitive positioning and innovation leadership.
Neurodegenerative Disease Market Scope
Leading Segments
By Indication
Parkinson's Disease
Alzheimer's Disease
Multiple Sclerosis
Huntington Disease
Others
By Drug
N-methyl-D-aspartate Receptor Antagonists
Cholinesterase Inhibitors
Dopamine Agonists
Immunomodulatory Drugs
Others
Leading Companies
AbbVie Inc
Amneal Pharmaceuticals Inc
Biogen Inc
Boehringer Ingelheim International GmbH
F. Hoffmann-La Roche Ltd
Johnson & Johnson
Merck & Co. Inc
Novartis AG
Pfizer Inc
Sanofi SA
Teva Pharmaceutical Industries Ltd
UCB S.A.
Geographies
North America- US, Canada, Mexico
Europe- Germany, France, UK, Spain, Italy, Nordics, BeNeLux, Others
Asia Pacific- China, India, Japan, South Korea, Australia, South East Asia, Others
Latin America- Brazil, Argentina, Others
Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
Reasons to Buy the Report
Table of Contents
182 Pages
- 1. Table of Contents
- List of Figures and Tables
- 2. Executive Summary
- 2.1 Key Highlights
- 2.1.1 Neurodegenerative Disease Market Size Outlook, 2018-2024 and 2025-2032
- 2.1.2 Largest Neurodegenerative Disease Market Types and Applications
- 2.1.3 Fastest Growing Segments
- 2.1.4 Potential Markets
- 2.1.5 Market Concentration
- 2.2 Market Scope and Segmentation
- 2.2.1 Market Scope- Segments
- 2.2.2 Market Scope- Countries
- 2.2.3 Macroeconomic and Demographic Outlook
- 2.2.4 Abbreviations
- 2.2.5 Units and Currency Conversions
- 3. Research Methodology
- 3.1 Primary Research Surveys
- 3.2 Secondary Data Sources
- 3.3 Data Triangulation
- 3.4 Forecast Methodology
- 3.5 Assumptions and Limitations
- 4. Introduction to Global Neurodegenerative Disease Market in 2025
- 4.1 Industry Panorama
- 4.2 Leading Companies Profiled in the Study
- 4.3 Asia Pacific Markets offer Robust Market Prospects for New Entrants
- 4.4 Market Dynamics
- 4.4.1 Market Dynamics- Trends and Drivers
- 4.4.2 Market Dynamics- Opportunities and Challenges
- 4.5 Regional Analysis
- 4.6 Porter’s Five Force Analysis
- 4.6.1 Intensity of Competitive Rivalry
- 4.6.2 Threat of New Entrants
- 4.6.3 Threat of Substitutes
- 4.6.4 Bargaining Power of Buyers
- 4.6.5 Bargaining Power of Suppliers
- 4.7 Neurodegenerative Disease Market Industry Value Chain Analysis
- 4.7.1 Stage of Value Chain
- 4.7.2 Key Activities of Companies
- 4.7.3 Companies Included in Each Stage
- 4.7.4 Key Insights
- 5. Neurodegenerative Disease Market Outlook to 2032
- 5.1 Market Size Forecast by Type, 2021-2024 and 2025-2032
- 5.2 Market Size Forecast by Application, 2021-2024 and 2024-2032
- 5.3 Market Size Forecast by Geography, 2021-2024 and 2024-2032
- By Indication
- Parkinson's Disease
- Alzheimer's Disease
- Multiple Sclerosis
- Huntington Disease
- Others
- By Drug
- N-methyl-D-aspartate Receptor Antagonists
- Cholinesterase Inhibitors
- Dopamine Agonists
- Immunomodulatory Drugs
- Others
- 6. Global Neurodegenerative Disease Market Outlook across Growth Scenarios
- 6.1 Low Growth Scenario
- 6.2 Base/Reference Case
- 6.3 High Growth Scenario
- 6. North America Neurodegenerative Disease Market Size Outlook
- 6.1 Key Market Statistics, 2024
- 6.2 North America Neurodegenerative Disease Market Trends and Growth Opportunities
- 6.2.1 North America Neurodegenerative Disease Market Outlook by Type
- 6.2.2 North America Neurodegenerative Disease Market Outlook by Application
- 6.3 North America Neurodegenerative Disease Market Outlook by Country
- 6.3.1 The US Neurodegenerative Disease Market Outlook, 2021- 2032
- 6.3.2 Canada Neurodegenerative Disease Market Outlook, 2021- 2032
- 6.3.3 Mexico Neurodegenerative Disease Market Outlook, 2021- 2032
- 7. Europe Neurodegenerative Disease Market Size Outlook
- 7.1 Key Market Statistics, 2024
- 7.2 Europe Neurodegenerative Disease Market Trends and Growth Opportunities
- 7.2.1 Europe Neurodegenerative Disease Market Outlook by Type
- 7.2.2 Europe Neurodegenerative Disease Market Outlook by Application
- 7.3 Europe Neurodegenerative Disease Market Outlook by Country
- 7.3.2 Germany Neurodegenerative Disease Market Outlook, 2021- 2032
- 7.3.3 France Neurodegenerative Disease Market Outlook, 2021- 2032
- 7.3.4 The UK Neurodegenerative Disease Market Outlook, 2021- 2032
- 7.3.5 Spain Neurodegenerative Disease Market Outlook, 2021- 2032
- 7.3.6 Italy Neurodegenerative Disease Market Outlook, 2021- 2032
- 7.3.7 Russia Neurodegenerative Disease Market Outlook, 2021- 2032
- 7.3.8 Rest of Europe Neurodegenerative Disease Market Outlook, 2021- 2032
- 8. Asia Pacific Neurodegenerative Disease Market Size Outlook
- 8.1 Key Market Statistics, 2024
- 8.2 Asia Pacific Neurodegenerative Disease Market Trends and Growth Opportunities
- 8.2.1 Asia Pacific Neurodegenerative Disease Market Outlook by Type
- 8.2.2 Asia Pacific Neurodegenerative Disease Market Outlook by Application
- 8.3 Asia Pacific Neurodegenerative Disease Market Outlook by Country
- 8.3.1 China Neurodegenerative Disease Market Outlook, 2021- 2032
- 8.3.2 India Neurodegenerative Disease Market Outlook, 2021- 2032
- 8.3.3 Japan Neurodegenerative Disease Market Outlook, 2021- 2032
- 8.3.4 South Korea Neurodegenerative Disease Market Outlook, 2021- 2032
- 8.3.5 Australia Neurodegenerative Disease Market Outlook, 2021- 2032
- 8.3.6 South East Asia Neurodegenerative Disease Market Outlook, 2021- 2032
- 8.3.7 Rest of Asia Pacific Neurodegenerative Disease Market Outlook, 2021- 2032
- 9. South America Neurodegenerative Disease Market Size Outlook
- 9.1 Key Market Statistics, 2024
- 9.2 South America Neurodegenerative Disease Market Trends and Growth Opportunities
- 9.2.1 South America Neurodegenerative Disease Market Outlook by Type
- 9.2.2 South America Neurodegenerative Disease Market Outlook by Application
- 9.3 South America Neurodegenerative Disease Market Outlook by Country
- 9.3.1 Brazil Neurodegenerative Disease Market Outlook, 2021- 2032
- 9.3.2 Argentina Neurodegenerative Disease Market Outlook, 2021- 2032
- 9.3.3 Rest of South and Central America Neurodegenerative Disease Market Outlook, 2021- 2032
- 10. Middle East and Africa Neurodegenerative Disease Market Size Outlook
- 10.1 Key Market Statistics, 2024
- 10.2 Middle East and Africa Neurodegenerative Disease Market Trends and Growth Opportunities
- 10.2.1 Middle East and Africa Neurodegenerative Disease Market Outlook by Type
- 10.2.2 Middle East and Africa Neurodegenerative Disease Market Outlook by Application
- 10.3 Middle East and Africa Neurodegenerative Disease Market Outlook by Country
- 10.3.1 Saudi Arabia Neurodegenerative Disease Market Outlook, 2021- 2032
- 10.3.2 The UAE Neurodegenerative Disease Market Outlook, 2021- 2032
- 10.3.3 Rest of Middle East Neurodegenerative Disease Market Outlook, 2021- 2032
- 10.3.4 South Africa Neurodegenerative Disease Market Outlook, 2021- 2032
- 10.3.5 Egypt Neurodegenerative Disease Market Outlook, 2021- 2032
- 10.3.6 Rest of Africa Neurodegenerative Disease Market Outlook, 2021- 2032
- 11. Company Profiles
- 11.1 Leading 10 Companies
- AbbVie Inc
- Amneal Pharmaceuticals Inc
- Biogen Inc
- Boehringer Ingelheim International GmbH
- F. Hoffmann-La Roche Ltd
- Johnson & Johnson
- Merck & Co. Inc
- Novartis AG
- Pfizer Inc
- Sanofi SA
- Teva Pharmaceutical Industries Ltd
- UCB S.A.
- 11.2 Overview
- 11.3 Products and Services
- 11.4 SWOT Profile
- 12. Appendix
- 12.1 Subscription Options
- 12.2 Customization Options
- 12.3 Publisher Details
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
